Evidence map›Paper›PMID 31588378›Full record

ArticleTranslational vision science & technology2019

Δ

Pranjal S Taskar, Akash Patil, Prit Lakhani, Eman Ashour, Waseem Gul, Mahmoud A ElSohly, Brian Murphy, Soumyajit Majumdar

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational vision science & technology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 30 citations in OpenAlex.

  1. Nanomaterials (Basel, Switzerland) · 2025
    Review
  2. Review
  3. Review
  4. Therapeutic Potential of Cannabinoids in Glaucoma.Pharmaceuticals (Basel, Switzerland) · 2023
    Review
  5. LC-MS/MS quantitation of non-psychotropic cannabinoid cannabidiol in aqueous humor.Journal of pharmaceutical and biomedical analysis · 2023
    Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Pranjal S TaskarDepartment of Pharmaceutics and Drug Delivery, University of Mississippi, Oxford, MS, USA.
Akash PatilDepartment of Pharmaceutics and Drug Delivery, University of Mississippi, Oxford, MS, USA.
Prit LakhaniDepartment of Pharmaceutics and Drug Delivery, University of Mississippi, Oxford, MS, USA.
Eman AshourDepartment of Pharmaceutics and Drug Delivery, University of Mississippi, Oxford, MS, USA.
Waseem GulElSohly Laboratories Inc., Oxford, MS, USA.
Mahmoud A ElSohlyDepartment of Pharmaceutics and Drug Delivery, University of Mississippi, Oxford, MS, USA.
Brian MurphyEmerald Bioscience Inc., Costa Mesa, CA, USA.
Soumyajit MajumdarDepartment of Pharmaceutics and Drug Delivery, University of Mississippi, Oxford, MS, USA.
University of Mississippi · USElSohly Laboratories (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeΔ

methodsSolid lipid nanoparticles (SLNs) of Δ

resultsA peak intraocular pressure (IOP) drop of 30% from baseline was observed in rabbits treated with SLNs loaded with Δ

conclusionΔ TRANSLATIONAL RELEVANCE: Glaucoma therapies usually focus on decreased aqueous humor production and increased outflow. However, such therapy is not curative, and there lies a need in preclinical research to focus efforts on agents that not only affect the aqueous humor dynamics but also provide neuroprotection. Historically, there have been bench-scale studies looking at retinal ganglion cell death post-axonal injury. However, for a smooth translation of this in vitro activity to the clinic, animal models examining IOP reduction, i.e., connecting the neuroprotective activity to a measurable outcome in glaucoma management (IOP), need to be investigated. This study investigated the IOP reduction efficacy of cannabinoids for glaucoma pharmacotherapy in a normotensive rabbit model, bringing forth a new class of agents with the potential of IOP reduction and improved permeation to the back of the eye, possibly providing neuroprotective benefits in glaucoma management.

Indexed as

glaucomaintraocular pressurenormotensivesolid lipid nanoparticlestetrahydrocannabinol

Identifiers

PMID31588378
PMCPMC6753841
OpenAlexW2973846764

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.